Table 1.
General characteristics of leukemia patients
| Parameters | AML | ALL |
|---|---|---|
| Gender (male/female) | 2/2 | 2/2 |
| Age (years) | 31.00 (22.00–50.50) | 33.00 (14.00–45.00) |
| WBCBlood (10E+9/L) | 4.40 (2.52–5.24) | 1.83 (0.51–7.92) |
| HbBlood (g/L) | 96.50 (73.75–120.00) | 111.50 (104.75–121.25) |
| PLTBlood (10E+9/L) | 273.50 (90.25–376.50) | 152.00 (76.25–312.50) |
| WBCCSF (10E+6/L) | 6.00 (3.00–13.50) | 6.00 (2.50–11.50) |
| BBB value | 8.39 (6.50–10.80) | 9.90 (7.03–13.18) |
| sVCAM-1CSF (pg/mL) | 1912.31 (913.69–2536.07) | 1534.97 (939.37–2018.74) |
| sVCAM-1Serum (ng/mL) | 349.95 (226.12–587.45) | 169.80 (96.07–266.06) |
| MMP-2CSF (pg/mL) | 680.96 (541.02–760.00) | 939.58 (825.12–1066.96) |
| MMP-2Serum (pg/mL) | 5363.81 (4320.50–6396.16) | 7064.78 (3426.89–8299.59) |
| MMP-9CSF (pg/mL) | 0.56 (0.51–0.62) | 0.57 (0.46–0.65) |
| MMP-9Serum (pg/mL) | 351.61 (190.44–725.71) | 401.90 (184.37–1395.83) |
| CXCL12CSF (pg/mL) | 318.66 (230.13–399.16) | 383.14 (290.50–447.28) |
| CXCL12Serum (pg/mL) | 435.15 (397.11–514.08) | 520.56 (362.34–823.28) |
| CCL2CSF (pg/mL) | 167.22 (86.48–268.20)* | 778.84 (451.29–996.19) |
| CCL2Serum (pg/mL) | 35.73 (32.27–63.83) | 58.96 (38.93–241.03) |
| VEGF-ACSF (pg/mL) | 127.90 (65.89–133.93) | 95.31 (79.63–152.82) |
| VEGF-ASerum (pg/mL) | 407.12 (272.38–542.58) | 597.48 (388.16–1259.95) |
Note:
*
P≤0.05 when the ALL group is compared with the AML group. Data shown as n (IQR).
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CSF, cerebrospinal fluid; WBC, white blood cell; Hb, hemoglobin; PLT, platelet; WBCCSF, WBC in CSF; IQR, inter-quartile range.